Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium · Delayed Price · Currency is EUR 4.610
+0.010 (0.22%)
Jul 22, 2026, 9:23 AM CET
Hyloris Pharmaceuticals Revenue
In the year 2025, Hyloris Pharmaceuticals had annual revenue of 7.21M EUR, down -14.79%. Hyloris Pharmaceuticals had revenue of 4.19M in the half year ending December 31, 2025, with 184.39% growth.
Revenue
7.21M
Revenue Growth
-14.79%
P/S Ratio
16.22
Revenue / Employee
144.35K
Employees
55
Market Cap
128.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.21M | -1.25M | -14.79% |
| Dec 31, 2024 | 8.46M | 6.37M | 305.27% |
| Dec 31, 2023 | 2.09M | 1.19M | 131.89% |
| Dec 31, 2022 | 900.00K | -2.20M | -70.93% |
| Dec 31, 2021 | 3.10M | 2.92M | 1,669.14% |
| Dec 31, 2020 | 175.00K | 84.00K | 92.31% |
| Dec 31, 2019 | 91.00K | - | - |
| Dec 31, 2018 | 91.00K | -122.00K | -57.28% |
| Dec 31, 2017 | 213.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 4.11B |
| European Medical Solutions | 52.80M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |
Hyloris Pharmaceuticals News
- 4 months ago - Hyloris Pharmaceuticals Annual report: H2 2025 - Filings
- 4 months ago - Hyloris Pharmaceuticals Earnings release: H2 2025 - Filings
- 10 months ago - Hyloris Pharmaceuticals Quarterly report: H1 2025 - Filings
- 10 months ago - Hyloris Pharmaceuticals Earnings release: H1 2025 - Filings